Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi-Aventis Nabs Deals

by Rick Mullin
August 3, 2009 | A version of this story appeared in Volume 87, Issue 31

Sanofi-Aventis and Merck reached an agreement under which Merck will sell its 50% interest in the companies' current animal health joint venture, Merial, to Sanofi-Aventis for $4 billion in cash. Merck, Sanofi-Aventis, and Schering-Plough also signed an agreement under which, following the closing of Merck's acquisition of Schering Plough, Sanofi-Aventis would have the option to combine the Intervet/Schering-Plough Animal Health business with Merial to form a new animal health joint venture with Merck. Meanwhile, Sanofi-Aventis says it has agreed to acquire a controlling interest in Indian vaccine maker Shantha Biotechnics for an undisclosed sum. Under the terms of the accord, Sanofi Pasteur, the vaccines unit of Sanofi-Aventis, will acquire ShanH, a division of Mérieux Alliance, a French biotechnology company that owns 80% of the Mumbai-based firm. The deal values Shantha, which is expected to have sales this year of about $90 million, at $776 million. Sanofi-Aventis has been on an acquisition streak in recent months, purchasing generic drug firms in Brazil and Mexico, and BiPar Sciences, a cancer drug firm in Brisbane, Calif. Earlier this year, the French drug major took over Zentiva, a Prague-based generic pharmaceutical firm serving Eastern Europe and Turkey.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.